Cumberland Pharmaceuticals Inc., of Nashville, Tenn., said it was awarded just over $1 million in funding from the FDA through the Orphan Drug Grant program to support a phase II study testing ifetroban, a thromboxane-prostanoid receptor antagonist, in cardiomyopathy associated with Duchenne muscular dystrophy in patients, 7 and older.